Advertisement

Topics

TolerRx Incorporated Company Profile

16:49 EDT 19th September 2017 | BioPortfolio

TolerRx, Inc. is an emerging biopharmaceutical enterprise specializing in the discovery, development, and commercial launch of a novel class of therapies that induce and/or maintain immunological tolerance. These therapies are most appropriate for chronic conditions associated with adverse, misdirected, or undesirable immune responses. TolerRx's approach is unique and unprecedented, in that it will leverage proprietary technology involving the identification of a fundamental mechanism of immunoregulation in order to discover therapies that induce long-standing immunological quiescence or tolerance.

Tolerance is a normal immunological response that the body uses to recognize "self" from "non-self" (foreign agents or antigens). By inducing a state of tolerance to inciting (or disease-causing) antigens, TolerRx's approach to disease intervention is closest to the cause or etiology of immune-mediated diseases. As such, TolerRx's therapies will utilize natural control mechanisms of the immune system, the result of which is a long-standing, antigen- and disease-specific clinical effect. The technology has applications in settings of transplantation, chronic biologic protein administration, gene therapy, and autoimmunity. As such, the technology has significant clinical development opportunities.



Until now, the strategies of immunosuppression have been based on direct control of the immune system by continuous application of drugs. Current immunosuppressive therapies penalize the entire immune system by disarming multiple mechanistic pathways. They must be administered continuously and for extended periods of time, and they have numerous deleterious side effects. Withdrawal of these drugs largely results in relapse of disease. TolerRx's new strategy is designed to harness the body's own T cell-mediated tolerance mechanisms that have presumably evolved so as to be minimally harmful to the host. Thus, the mission of TolerRx is to create therapies aimed at reprogramming the immune system by changing its perception of disease-related or "self" antigens so as to become tolerant to them while preserving normal immunological competence.

Location

300 Technology Square, 4th Floor
Cambridge
MA
02139
United States of America

Contact

Phone: 617-354-8100
Fax: 617-354-8300
Email: info@TolerRx.com


News Articles [2 Associated News Articles listed on BioPortfolio]

Corcept Therapeutics Announces Presentations on Mifepristone for the Treatment of Patients with Hypercortisolism at the American Association of Clinical Endocrinologists 26th Annual Congress

MENLO PARK, CA -- (Marketwired) -- 05/04/17 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that tre...

Milestone Scientific Announces Children's Hospital of Pittsburgh to use The Wand(R) Computer Assisted Anesthesia System for Pediatric Patients

LIVINGSTON, NJ --(Marketwired - September 14, 2017) - Milestone Scientific Inc. (NYSE American: MLSS) (NYSE MKT: MLSS), a medical company that develops and commercializes a growing portfolio of propri...

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

AERODYNAMIC PROPERTIES AND IN SILICO DEPOSITION OF MELOXICAM POTASSIUM INCORPORATED IN A CARRIER-FREE DPI PULMONARY SYSTEM.

Dry powder inhalers (DPIs) have been among the fastest developing inhaler forms in the past decades. Researches are focusing on the formulation of carrier-free powders to obtain a higher deep-lung dep...

Clinical Trials [0 Results]

None

Companies [38 Associated Companies listed on BioPortfolio]

Toler RX Incorporated

TolerRx, Inc. is an emerging biopharmaceutical enterprise specializing in the discovery, development, and commercial launch of a novel class of therapies that induce and/or maintain immunological tole...

TolerRx Incorporated

TolerRx, Inc. is an emerging biopharmaceutical enterprise specializing in the discovery, development, and commercial launch of a novel class of therapies that induce and/or maintain immunological tole...

TolerRx, Inc.

We are a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies to treat patients with immunological diseases. TolerRx has a development pipeline whi...

PRAECIS PHARMACEUTICALS INCORPORATED

PRAECIS PHARMACEUTICALS INCORPORATED is a biopharmaceutical company focused on the discovery and development of novel compounds to address unmet medical needs or improve existing therapies.PRAECIS has...

Pharmapraxis

Founded in 2008 by the Axis Biotec Brasil™ group (www.axisbiotec.com.br), PharmaPraxis has incorporated technologies, and will develop and launch biologic products in Brazil....

More Information about "TolerRx Incorporated" on BioPortfolio

We have published hundreds of TolerRx Incorporated news stories on BioPortfolio along with dozens of TolerRx Incorporated Clinical Trials and PubMed Articles about TolerRx Incorporated for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of TolerRx Incorporated Companies in our database. You can also find out about relevant TolerRx Incorporated Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...


Corporate Database Quicklinks



Searches Linking to this Company Record